8 News & Press Releases found
ImCare Biotech, LLC News
-
Independent Clinical Study Shows Seravue® Has High Sensitivity And Specificity For The Detection Of Liver Cancer In Nafld And Related Cirrhotic Patients
A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma ...
-
ImCare Biotech awarded up to $4M Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH) to support commercialization and approval of Seravue
ImCare Biotech has been awarded a Phase IIB Bridge Award by the National Cancer Institute (NCI/NIH). This up to $4M over three-year award will be used to help ImCare Biotech pursue commercialization activities and support a pivotal ...
-
The Centers for Medicare and Medicaid (CMS) announced the MCIT pathway to provide national Medicare coverage for FDA Breakthrough Devices and Diagnostic
The Centers for Medicaid and Medicare (CMS) announced the establishment of the MCIT (Medicare Coverage of Innovative Technology) pathway, which is designed to provide coverage and access to new, innovative medical devices and diagnostics which ...
-
FDA grants Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular ...
-
FDA grants Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
ImCare Biotech has been awarded Phase II grant by NCI (NIH)
ImCare Biotech has been awarded Phase II grant by NCI (NIH) for its project on development of a diagnostic kit for early detection of liver cancer.